Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- In trials, not approved
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Caseanine; (-)-corydalis b; Gindarine; Hyndarine; Levo-tetrahydropalmatine; L-tetrahydropalmatine; (-)-rotundine; Rotundine; (-)-tetrahydropalmatine; Tetrahydropalmatine
- Note
- Not recorded
Clinical trials 4
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder
Cocaine Use
Enrolment: 0 · Results not recorded
Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use
Cocaine Use
Enrolment: 20 · Results not recorded
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Enrolment: 63 · Results not recorded
Pilot Study to Investigate the Efficacy of Pain Bloc-R (contains l-THP) in Healthy Participants With Non-pathological Aches and Discomfort
Healthy
Enrolment: 27 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinBalb/cMalen = 108 mice in six groups of 18, with 6 sacrificed per time po…Oral, dissolved in 1% DMSO20 or 40 mg/kg in vivo; 15 and 30 microM in vitroPretreatment for 5 days before concanavalin A injection
Model: Concanavalin A-induced acute autoimmune hepatitis, 25 mg/kg via tail vein
Levo-tetrahydropalmatine pretreatment dose-dependently lowered transaminases, necrosis, TNF-alpha and IL-6, apoptosis and autophagy markers, and TRAF6 and phospho-JNK.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
